Reviva pharmaceuticals announced preclinical efficacy data on brilaroxazine in ipf at the 2023 american thoracic society international conference and publication in medical research archives

Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (ipf)

RVPH Ratings Summary

RVPH Quant Ranking